​

Mersana Therapeutics (MRSN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRSN Stock Forecast

Mersana Therapeutics (MRSN) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a 809.09% increase from the last price of $0.33.

- $1 $2 $3 $4 $5 $6 High: $3 Avg: $3 Low: $3 Last Closed Price: $0.33

MRSN Stock Rating

Mersana Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (73.68%), 5 Hold (26.32%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 5 14 Strong Sell Sell Hold Buy Strong Buy

MRSN Price Target Upside V Benchmarks

TypeNameUpside
StockMersana Therapeutics809.09%
SectorHealthcare Stocks 35.46%
IndustryBiotech Stocks 87.81%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$0.33$0.33$0.33
Upside/Downside--809.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-81--9
Mar, 25-82--10
Feb, 25-82--10
Jan, 25-82--10
Dec, 24-82--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2024Collen KusyRobert W. Baird$3.00$1.35122.22%809.09%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 11, 2025BTIGBuyBuyhold
Nov 15, 2024CitigroupBuyBuyinitialise
Feb 29, 2024GuggenheimUnderperformUnderperformhold
Feb 29, 2024WedbushOutperformupgrade
Feb 28, 2024BTIGBuyupgrade
Dec 04, 2023CitigroupBuyupgrade
Jul 27, 2023Piper SandlerOverweightinitialise
Jun 15, 2023GuggenheimBuyinitialise
Feb 18, 2022SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.44$-2.40$-2.22$-1.48$-0.56----
Avg Forecast$-1.31$-2.36$-2.25$-1.46$-0.60$-0.66$-0.71$-0.80$-0.47
High Forecast$-0.53$-0.95$-1.47$-1.39$-0.54$-0.43$-0.45$-0.46$-0.26
Low Forecast$-1.93$-3.46$-3.10$-1.57$-0.66$-0.97$-0.93$-1.08$-0.72
Surprise %9.92%1.69%-1.33%1.37%-6.67%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$828.00K$43.00K$26.58M$36.85M$40.50M----
Avg Forecast$1.01M$27.71K$26.29M$40.91M$31.72M$27.74M$44.83M$21.91M$117.80M
High Forecast$1.38M$37.73K$33.86M$46.55M$36.14M$39.59M$44.84M$31.27M$168.11M
Low Forecast$546.03K$14.95K$19.22M$30.53M$26.11M$18.50M$44.82M$14.61M$78.56M
Surprise %-18.19%55.16%1.09%-9.91%27.68%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-88.40M$-169.21M$-207.54M$-171.67M$-69.19M----
Avg Forecast$-75.72M$-148.26M$-173.38M$-171.67M$-74.62M$-93.59M$-79.71M$-119.67M$-54.11M
High Forecast$-60.57M$-118.61M$-138.70M$-137.34M$-62.90M$-49.63M$-52.01M$-53.79M$-30.68M
Low Forecast$-90.86M$-177.91M$-208.05M$-206.00M$-76.63M$-112.90M$-107.41M$-125.89M$-84.15M
Surprise %16.76%14.13%19.71%--7.27%----

MRSN Forecast FAQ

Is Mersana Therapeutics stock a buy?

Mersana Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mersana Therapeutics is a favorable investment for most analysts.

What is Mersana Therapeutics's price target?

Mersana Therapeutics's price target, set by 19 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential 809.09% change from the previous closing price of $0.33.

How does Mersana Therapeutics stock forecast compare to its benchmarks?

Mersana Therapeutics's stock forecast shows a 809.09% upside, outperforming the average forecast for the healthcare stocks sector (35.46%) and outperforming the biotech stocks industry (87.81%).

What is the breakdown of analyst ratings for Mersana Therapeutics over the past three months?

  • April 2025: 0% Strong Buy, 88.89% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Mersana Therapeutics’s EPS forecast?

Mersana Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.66, marking a 17.86% increase from the reported $-0.56 in 2024. Estimates for the following years are $-0.71 in 2026, $-0.8 in 2027, and $-0.47 in 2028.

What is Mersana Therapeutics’s revenue forecast?

Mersana Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $27.74M, reflecting a -31.50% decrease from the reported $40.5M in 2024. The forecast for 2026 is $44.83M, followed by $21.91M for 2027, and $117.8M for 2028.

What is Mersana Therapeutics’s net income forecast?

Mersana Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-93.586M, representing an 35.26% increase from the reported $-69.192M in 2024. Projections indicate $-79.709M in 2026, $-120M in 2027, and $-54.109M in 2028.